Form 4: Vertex Pharmaceuticals EVP and CMO Carmen Bozic Reports Sale of Common Stock

Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, reported the sale of 2,280 shares of common stock on June 12, 2024, at a price of $478 per share.

Summary

• On June 12, 2024, Carmen Bozic, the Executive Vice President and Chief Medical Officer (EVP and CMO) of Vertex Pharmaceuticals, sold 2,280 shares of the company's common stock.
• The sale was executed at a price of $478 per share.
• Following the transaction, Bozic directly owns 32,379 shares of Vertex Pharmaceuticals' common stock.
• The transaction was made pursuant to a pre-arranged trading plan under Rule 10b5-1, which was established on February 27, 2024.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to a stock sale by an executive. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. They can be influenced by various factors, including personal financial planning and diversification strategies. Rule 10b5-1 plans are often used to avoid accusations of insider trading.

Stakeholder Impact

• The sale of shares by an executive could be perceived neutrally or slightly negatively by shareholders, depending on the context and the size of the sale, but is unlikely to have a significant impact given the existence of the 10b5-1 trading plan.

Key Dates